5/12/2022 4:07:12 PM
CTI BioPharma Q1 Loss/share $0.37 Vs. Loss $0.23 Year Ago
4/14/2022 7:05:53 AM
CTI BioPharma Says NCCN Guidelines Recommend VONJO For Myeloproliferative Neoplasm
3/31/2022 4:04:34 PM
CTI BioPharma Q4 Loss/share $0.38 Vs. Loss $0.20 Year Ago
12/13/2021 9:04:39 AM
CTI BioPharma Presents Data From Pacritinib Program
11/29/2021 7:02:48 AM
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/25/2021 7:01:27 AM
CTI BioPharma And DRI Healthcare Trust Announce Up To $135 Mln Debt And Royalty Transaction
8/24/2021 7:02:27 AM
CTI BioPharma Appoints Diane Parks To Board